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I.

INTRODUCTION

“I just killed my two daughters . . . I just freaked out . . . I
stabbed them,” declared David Crespi on the phone with a 9-1-1

* J.D. Candidate, 2015, The John Marshall Law School, Chicago, Illinois;
B.A., 2010, University of Denver. I want to thank Erin Wilson for taking me
under her wing during my summer at the Fort Collins Public Defender’s Office
in Colorado. The work you did to help Stephanie not only inspired this Comment
but also ignited my passion to become a public defender. To my friends and
family near and far: thank you for the continuous support throughout these
challenging and fulfilling law school years. I hope to make you proud.
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operator. 1
“[Lorie Jeror] had come running over here to say her son hit
her husband with an ax . . . She thought he was dead,” remembered
a neighbor, Rick Williams. 2
“I shot both boys in the head. I think I shot Jamie twice. I think
I shot one of them twice,” Leslie Demeniuk purportedly told
detectives about her four-year-old twin sons. 3

A. The United States and Antidepressants: A Sad
Overview
For many Americans, antidepressants have become a
prescriptive life support. During the six years from 1988 to 1994,
antidepressant usage increased four hundred percent. 4 An
estimated 264 million antidepressant prescriptions were written in
2011. 5 And now one in every ten Americans over the age of twelve

1. David Lauren CRESPI: David Crespi 9-1-1 Tape Released, MURDERPEDIA
(Oct. 4, 2006), http://murderpedia.org/male.C/c/crespi-david-911-call.htm. See
also 911 Call, CRESPI FAMILY HOPE, http://www.crespifamilyhope.org/ourjourney/horror/ (last visited Mar. 16, 2015) (providing the entire audio of the
911 call made by David Crespi); see also Alison Lynn, Family’s “Perfect Life”
Shattered,
ABC NEWS, http://abcnews.go.com/TheLaw/story?id=498783
7&page=1 (last visited Mar. 16, 2015) (retelling the story of David Crespi’s
battle with his mental health, and how his underlying bipolar disease went
undiagnosed and lead to the death of his twin daughters).
2. Denise A. Raymo, Teen Charged in Ax Attack: Son Allegedly Tried to Kill
his Father, State Troopers Say, PRESS-REPUBLICAN (Jan. 18, 2005),
http://blog.pressrepublican.com/archive/index.php?option=com_content&view=
article&id=27109:teen_charged_in_ax_attack:_son_allegedly_tried_to_kill_his
_father,_state_troopers_say&catid=34:news-articles&Itemid=64.
3. Trial Begins of Mother Accused of Killing 4-Year-Old Twins, NEWS4JAX,
http://www.news4jax.com/news/Trial-Begins-Of-Mother-Accused-Of-Killing-4Year-Old-Twins/-/475880/1902524/-/lctn4yz/-/index.html (last updated Jan. 4,
2006). See also Leslie Demeniuk, MURDERPEDIA, http://murderpedia.org/
female.D/d/demeniuk-leslie.htm (last visited Mar. 16, 2015) (listing numerous
other articles and websites detailing Leslie Demeniuk’s murder of her twin boys
and the role of antidepressants in their deaths). This Comment uses these three
stories to demonstrate that taking antidepressants, often in conjunction with
other medications, can lead to homicide and violence. Although this Comment
focuses on several awful reactions to antidepressants, these are outliers. This
Comment should not be understood to question the use of antidepressants all
together, but, rather, to increase awareness of the rare effects that can and do
occur.
4. NAT’L CTR. FOR HEALTH STATISTICS, HEALTH, UNITED STATES, 2010:
WITH SPECIAL FEATURE ON DEATH AND DYING 19 (2011) [hereinafter NCHS,
HEALTH, U.S. 2010], available at http://www.cdc.gov/nchs/data/hus/hus10.pdf.
5. IMS HEALTH, NATIONAL PRESCRIPTION AUDIT (2011), cited in IMS
INSTITUTE FOR HEALTHCARE INFORMATICS, THE USE OF MEDICINES IN THE
UNITED STATES: REVIEW OF 2011 37 (2012), available at http://www.imshealth.
com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20I
nformatics/IHII_Medicines_in_U.S_Report_2011.pdf
[hereinafter
IMS
INSTITUTE].
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takes an antidepressant. 6 In 2011, antidepressants became the
most dispensed prescription drug, 7 in turn accounting for $11 billion
in spending on antidepressants in the pharmaceutical industry. 8
The leaders of this drug revolution are none other than primary care
physicians, the “gatekeepers of medical care.” 9 Unsurprisingly, an
immense variety of antidepressants are available on the market, as
demonstrated
by
the
ever-pervasive
direct-to-consumer
advertisements. 10
Despite this overwhelming demand, more recent scientific
studies suggest that antidepressants are only moderately effective
in helping with depression. 11 The antidepressants most commonly
used and prescribed 12 are from the selective serotonin reuptake
inhibitor (SSRI) 13 or serotonin-norepinephrine reuptake inhibitor
6. Laura A. Pratt et al., Antidepressant Use in Persons Aged 12 and Over:
United States, 2005–2008, NCHS DATA BRIEF (Nat’l Ctr. for Health Statistics,
Hyattsville, MD), No. 76, Oct. 2011, at 1, available at http://www.cdc.gov/nchs/
data/databriefs/db76.pdf.
7. IMS HEALTH, supra note 5.
8. IMS HEALTH, NATIONAL SALES PERSPECTIVES (2011), cited in IMS
INSTITUTE, supra note 11, at 42. Antidepressants ranked seventh out of the
twenty classes listed in the IMS Health’s study of “Top Therapeutic Classes by
Spending.” Id.
9. Joseph A. Lieberman III, History of the Use of Antidepressants in Primary
Care, 5 PRIMARY CARE COMPANION J. CLIN. PSYCHIATRY 6, 6 (2003).
10. See generally Nathan D. Greenslit & Ted J. Kaptchuk, Antidepressants
and Advertising: Psychopharamceuticals in Crisis, 85 YALE J. BIOLOGY & MED.
153, 154–57 (2012), available at http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3313530/pdf/yjbm_85_1_153.pdf
(arguing
how
marketing
oversimplifies the complex relationship between taking medication and mental
illness); Jeffery R. Lacasse & Jonathan Leo, Serotonin and Depression: A
Disconnect between the Advertisements and the Scientific Literature, 2 PLOS
MED. 1211, 1211 (2005), available at http://www.plosmedicine.org/article/info:
doi/10.1371/journal.pmed.0020392 (demonstrating the disconnect by citing to
“Zoloft’s miserably depressed ovoid creature” advertisements).
11. N. R. Horn, Issues in Treating Depression in Primary Care: The Last
Decade has Provided a Better Evidence Base for Treating Depression, 31
CONTINUING MED. EDUC. 46 (2013) (analyzing the effectiveness of
antidepressants and explaining that the misreporting of clinical drug trial
results by parties with a stake in the outcome leads to further misinterpretation
of the data). See also Robert D. Gibbons et al., Benefits from Antidepressants:
Synthesis of 6-Week Patient-Level Outcomes from Double-Blind PlaceboControlled Randomized Trials of Fluoxetine and Venlafaxine, 69 ARCH. GEN.
PSYCHIATRY 572, 576–77 (2012) (finding that only one in five treated patients
will respond to either fluoxetine or vanlafaxine); but see Konstantinos N.
Fountoulakis et al., No Role for Initial Severity on the Efficacy of
Antidepressants: Results of a Multi-meta-analysis, 12 ANNALS GEN.
PSYCHIATRY 1, 1 (2003), available at http://www.annals-general-psychiatry.
com/content/12/1/26 (finding that antidepressants are more effective than
placebos).
12. NAT’L INST. OF MENTAL HEALTH, MENTAL HEALTH MEDICATIONS 4
(2010), available at http://www.nimh.nih.gov/health/publications/mentalhealth-medications/NIMH-Mental-Health-Medications_45027.pdf.
13. See Selective Serotonin Reuptake Inhibitors (SSRIs) Information, U.S.
FOOD AND DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/Informationby
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(SNRI) 14 family of drugs. Further, the myriad of potential, and often
realized, side effects caused by antidepressants generates
substantial concern. 15 This array of physical health side effects 16
includes diarrhea, nausea, and even loss of libido. 17 Even
exceedingly grave and violent “adverse events,” 18 like suicide 19 and
homicide, 20 are occurring more frequently than pharmaceutical
companies let on. 21 Such risks are magnified when antidepressants
DrugClass/ucm283587.htm (last updated Dec. 23, 2014) (listing the generic and
brand name SSRIs approved by the FDA and on the market).
14. Diseases and Conditions: Serotonin and Norepinephrine Reuptake
Inhibitors (SNRIs), MAYO CLINIC (June 6, 2013), http://www.mayoclinic.org/
diseases-conditions/depression/in-depth/antidepressants/art-20044970.
15. Roni C. Rabin, A Glut of Antidepressants, N.Y. TIMES, Aug. 13, 2013, at
D4, available at http://well.blogs.nytimes.com/2013/08/12/a-glut-of-antidepress
ants/?_r=0; see generally John A. Cohan, Psychiatric Ethics and Emerging
Issues of Psychopharmacology in the Treatment of Depression, 20 J. CONTEMP.
HEALTH L. & POL’Y 115 (2003) (discussing the effectiveness of SSRI
antidepressants and whether the numerous side effects are worth the potential,
serious risks); May L. Harris, Comment, Problems with Prozac: A Defective
Product Responsible for Criminal Behavior?, 10 J. CONTEMP. LEGAL ISSUES 359
(1999) (analyzing the effect of Prozac in the clinical studies and later in the
market and discussing the story of William Forsyth, Sr., who stabbed and
murdered his wife after ten days on Prozac).
16. Elisa Cascade, Amir H. Kalali & Sidney H. Kennedy, Real-World Data
on SSRI Antidepressant Side Effects, 6 PSYCHIATRY 16, 16 (Feb. 2009), available
at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719451/pdf/PE_6_2_16.pdf.
The Real-World Data Article sampled a pool of about 700 patients taking an
SSRI antidepressant. Id. Of those patients in the survey, thirty-eight percent
(229 patients) “reported experiencing one or more side effects as a result of
taking an SSRI antidepressant.” Id. Out of those patients experiencing at least
one side effect, astonishingly, “only [forty] percent of patients mentioned the
side effects to their prescribing physicians.” Id.
17. CONSUMER REPORTS, BEST BUY DRUGS 10, 21–23 (2013), available at
http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/Antidepr
essants_update.pdf.
18. See generally Norman M. Goldfarb, Adverse Event Terminology, 8 J.
CLINICAL RESEARCH BEST PRACTICES 1 (2012), available at http://firstclinical.
com/journal/2012/1207_Adverse.pdf (listing different definitions of “adverse
event” created by United States agencies and institutes and international
organizations). The Code of Federal Regulations provides the working definition
of “adverse event” that the FDA uses. Under that definition, an “adverse event”
is “any untoward medical occurrence associated with the use of a drug in
humans, whether or not considered drug related.” 21 C.F.R. § 312.32 (2013).
19. See generally W. Creaney et al., Antidepressant Induced Suicidal
Ideation, 6 HUMAN PSYCHOPHARMACOLOGY 329 (1991), available at
http://www.davidhealy.org.php53-23.dfw1-1.websitetestlink.com/wp-content/
uploads/2012/05/1991-Creaney-Healy-Prozac-Suicide1.pdf
(exploring
the
occurrence of suicidal ideation in people who had been taking antidepressants
for just a matter of days).
20. Joseph Mercola, He Murdered a Friend after Taking this Best-Selling
Drug, MERCOLA (Feb. 25, 2012), http://articles.mercola.com/sites/articles/
archive/2012/02/25/legal-system-rules-antidepressants-cause-kids-to-kill.aspx.
21. John LaMattina, Can Pharma Hide Side Effects of Marketed Drugs in
the U.S.?, FORBES (Sept. 3, 2013), http://www.forbes.com/sites/johnlamattina/
2013/09/03/can-pharma-hide-side-effects-of-marketed-drugs-in-the-u-s/
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are used as part of a “cocktail” with other drugs. 22 Essentially,
doctors are handing their patients’ “ticking time bombs” with only
a simple signature on their prescription notepads. 23
The three stories of death and tragedy referenced at the start
of this Comment represent a small sample of the many such heinous
occurrences. 24 Criminal consequences logically stem from instances
where antidepressant-prescribed patients suffer from adverse
events that result in violence. 25 Over the past couple of decades,
courts have been exposed to evidence that these drugs contribute to,
or even solely cause, violent behaviors and mental states. 26 But
criminal defendants have largely been left to suffer the
consequences of these rare side effects with no hope for justice in
the courts.
This Comment explains how the commonly prescribed SSRI
(demonstrating the commentary that erupts around antidepressant side effects
and how much the pharmaceutical companies actually report to consumers);
Gardiner Harris, Spitzer Sues a Drug Maker, Saying it Hid Negative Data, N.Y.
TIMES (June 3, 2004), http://www.nytimes.com/2004/06/ 03/business/spitzersues-a-drug-maker-saying-it-hid-negative-data.html?pagewanted=all&src=pm
(reporting on GlaxoSmithKline’s failure to warn doctors that Paxil can cause
suicide in young adults, the choice to promote the prescribing of Paxil to
adolescents, and the FDA’s subsequent decision to require black box label
warnings on Paxil).
Federal law requires that pharmaceutical companies report adverse drug
experiences both during and after approval. 21 C.F.R. § 312.32 (2013). Also,
there exists a variety of reporting websites that are not tied directly to
pharmaceutical companies or the FDA. MEDIGUARD, https://www.mediguard.
org (last updated Nov. 1, 2013) (providing a resource for patients to engage in
research on prescriptions by reported side effects, satisfaction with drugs (or
lack thereof), and other feedback); RXISK, https://www.rxisk.org (last visited
Mar. 19, 2015). But reporting rates sometimes remain low. Cascade, supra note
16, at 16 (finding that “only [forty] percent of patients mention the side effects
[of antidepressant use] to their prescribing physicians”).
22. See Carmine Nieuwstraten et al., Systematic Overview of Drug
Interactions with Antidepressant Medications, 51 CAN. J. PSYCHIATRY 300, 302
(2006) (finding that SSRIs accounted for thirty-two percent of negative drug
interactions reported and tricyclic antidepressants accounted for thirty-three
percent of negative drug interactions reported).
23. Diane E. Hadley et al., Psychiatric Drug Interactions Explored: From the
Literature to Clinical Practicality, Feb. 2012 PHARMACY PRACTICE NEWS 7–12,
available
at
http://www.pharmacypracticenews.com/download/ppn0212_
ER_WM.pdf.
24. See SSRI Stories: Antidepressant Nightmares, SSRO STORIES
http://ssristories.org/ (last visited Mar. 27, 2015) [hereinafter SSRI Stories]
(listing over 4,800 media articles in which antidepressants are mentioned, many
of which detail criminal activity by those taking SSRIs and SNRIs); RXISK,
supra note 21 (offering a database of side effects and stories organized by a
search of the prescription drug’s name).
25. Thomas J. Moore et al., Prescription Drugs Associated with Reports of
Violence Towards Others, 5 PLOS ONE 1, 2–4 (2010), available at
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.00153
37.
26. See Cohan, supra note 15, at 146–58 (describing how courts have seen
the appearance of antidepressants in both the criminal and civil arenas).
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and SNRI antidepressants, particularly the SNRI Effexor, can
cause people to commit murder and proposes how an untraditional
but commonly recognized criminal defense should be applied to such
people. Part II begins with a brief discussion of how antidepressants
were invented and gained sweeping popularity. Part II also
highlights a few of the court cases confronting their potential to
drive normal individuals to murder. Part III analyzes two defenses,
involuntary intoxication and automatism, which a criminal
defendant taking antidepressants could raise to avoid being
unjustly convicted. After a comparison of these two defenses, Part
IV proposes that courts accept automatism as a viable defense for
criminal defendants who take Effexor and then commit homicide.
Automatism could function as either a complete defense (absolute
exoneration) or as a partial defense (sentence mitigation). In giving
life to the automatism defense, courts should consider the latest
scientific findings about the link between genetic mutations and
one’s inability to process drugs and the resulting toxic effects.

II. AMERICA’S INTRODUCTION TO THE WONDER DRUG
A. A Brief History of Antidepressants in the United
States
During a study to find a treatment for tuberculosis in 1952,
scientists made an unexpected discovery. 27 They found that
iproniazid, an antimycobacterial agent, had psychoactive properties
that caused terminally ill patients to respond in positive and
optimistic ways. 28 This discovery led to the creation of the first class
of antidepressant drugs known as monoamine oxidase inhibitors
(MAOIs). 29 However, MAOIs were not clinically tested for
depression for another decade. 30 In the meantime, imipramine,
which was developed around the same time as iproniazid, became
“the first clinically useful tricyclic antidepressant (TCA).” 31 During
the 1960s, clinical trials demonstrated that TCAs were better than
MAOIs. 32 This decade also saw significant scientific advancement
in the understanding of the human nervous system. 33 The
“serotonin hypothesis” was born shortly after this better
understanding and is now commonly used to explain how a person’s
serotonin levels seemingly hold the key to their happiness. 34
27. Lieberman, supra note 9, at 6.
28. Id.
29. Id.
30. Id.
31. Id.
32. Id. at 7.
33. Id.
34. Id. Joseph Schildkraut posited the “serotonin hypothesis” in 1965 when
research indicated that depression occurred because of reduced levels of
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From the 1970s into the 1990s, a myriad of new SSRIs were
developed and tested. 35 In 1988, the Food and Drug Administration
(FDA) approved the first SSRI, Eli Lilly and Company’s fluoxetine
– Prozac was born. 36 The SSRI family of antidepressants was safer 37
and seemed to be more successful in helping patients with
depression. 38 SSRIs, “the first-line pharmacotherapy for major
depressive disorder throughout much of the industrialized world,”
however, did not treat severe depression as well as some of the
earlier developed TCAs. 39 Eventually SNRIs were developed to have
the efficacy of prior TCAs but with the “kinder” side effects of
SSRIs. 40 As antidepressants became more widely available and
safer, psychiatrists continuously lost their role as the main
providers of antidepressant prescriptions. 41 Instead, primary care
physicians began writing these prescriptions and quickly became
“among the most frequent prescribers of new-generation
antidepressant medications in the United States.” 42
1. FDA Approval Procedures
To get FDA approval, a drug company must pass animal
testing and then three phases of human clinical trials. 43 During
Phase One of human testing, the new drug is given to humans to
“determine the metabolism and pharmacologic actions of the
drug.” 44 Phase Two focuses on the effectiveness of the new drug on
patients that have the particular disease or condition the drug is

norepinephrine. Lacasse, supra note 10, at 1211. The ultimate version of this
theory claimed that the serotonin neurotransmitter holds the key to relieving
depression. Id. This theory has even affected pharmaceutical companies’
television commercials. The cartoon commercials for Zoloft have little balls of
serotonin bouncing back and forth between receptors, making the little circle
character happy once again. Id.; see also SuperBowlSammy, Original Zoloft
Commercial, YOUTUBE, (Mar. 19, 2009), http://www.youtube.com/watch?v=tw
hvtzd6gXA.
35. Lieberman, supra note 9, at 7.
36. Harris, supra note 15, at 360.
37. Id.
38. Id.
39. Michael E. Thase, MD, Are SNRIs More Effective than SSRIs? A Review
of the Current State of the Controversy, PSYCHOPHARMACOLOGY BULLETIN (July
28, 2008), available at http://www.medscape.org/viewarticle/578077.
40. Id.
41. Harris, supra note 15, at 360.
42. Id.
43. Id. at 372.
44. 21 C.F.R. § 312.21(a)(1). The purpose of Phase One is also to determine
“the side effects associated with increasing doses, and, if possible, to gain early
evidence on effectiveness. During Phase [One], sufficient information about the
drug's pharmacokinetics and pharmacological effects should be obtained to
permit the design of well-controlled, scientifically valid, Phase [Two] studies.”
Id. The number of tested patients is usually between twenty and eighty. Id.
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supposed to remedy. 45 Finally, Phase Three incorporates both
controlled and uncontrolled studies. 46 After these studies, the FDA
determines whether any further information about effectiveness or
safety is needed to “evaluate the overall benefit-risk relationship of
the drug.” 47 If not, the FDA determines if the drug receives final
approval. If the drug is given final approval, the FDA instructs the
manufacturer what particular warnings must be included when
marketing the new drug. 48 From that point forward, the FDA must
authorize any future changes to the drug’s warning label. 49
2. Current, Well-Known Antidepressants on the Market
Fluoxetine, advertised under the brand name Prozac, was the
first of the many well-known SSRI antidepressants. Today, there
are six major SSRIs on the market: citalopram (Celexa), 50
escitalopram (Lexapro), 51 fluoxetine (Prozac), 52 fluvoxamine
maleate (Luvox), 53 paroxetine (Paxil), 54 and sertraline (Zoloft). 55
These antidepressants are generally the most well-known, as they
were heavily marketed from their creation. 56
45. Id. § 312.21(b). This section of the code further notes that the study is
looking “to determine the common short-term side effects and risks associated
with the drug” through a much tighter monitoring process and a bigger pool of
patients, around several hundred. Id.
46. Id. § 312.21(c).
47. Id. The Third Phase typically involves several hundred to several
thousand participants. Id. After this final phase, the FDA will have enough
information on side effects, safety, and overall effectiveness to determine what
to require on the prescription labeling. Id.
48. Harris, supra note 15, at 372.
49. See 21 C.F.R. § 314.70 (detailing the process for changing warnings by
FDA approval after a new drug’s initial approval).
50. Citalopram (marketed as Celexa) Information, U.S. FOOD AND DRUG
ADMIN.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa
tientsandProviders/ucm053339.htm (last updated Nov. 21, 2012).
51. Escitalopram (marketed as Lexapro) Information, U.S. Food and Drug
Admin., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053342.htm (last updated Dec. 16, 2014).
52. Fluoxetine (marketed as Prozac) Information, U.S. FOOD AND DRUG
ADMIN.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109352.htm (last updated Dec. 16, 2014).
53. Fluvoxamine Maleate Information, U.S. FOOD AND DRUG ADMIN.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa
tientsandProviders/ucm113425.htm (last updated June 26, 2013).
54. Paroxetine (marketed as Paxil) Information, U.S. FOOD AND DRUG
ADMIN.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessio
nals/ucm085313.htm (last updated June 26, 2013).
55. Sertraline (marketed as Zoloft) Information, U.S. FOOD AND DRUG
ADMIN.,
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053351.htm (last updated Apr. 29, 2013).
56. Thase, supra note 39.
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The other major family of antidepressant drugs, SNRIs, was
developed throughout the 1990s and early 2000s to provide better
results for severe depression than SSRIs, all the while reducing the
side effects reminiscent of the older TCAs. 57 There are currently
four FDA-approved SNRIs on the market: 58 desvenlafaxine
(Pristiq), 59 duloxetine (Cymbalta), 60 levomilnacipran hydrochloride
(Fetzima), 61 and venlafaxine, commonly called Effexor. 62 Effexor is
the focus of this Comment.

B. The FDA Requires “Black Box” Label on all
Antidepressants
Suicidal thoughts by patients taking antidepressants were
reported as early as 1990. 63 Then in the early 2000s, public concern
over children and adolescent suicides due to antidepressant use
grew substantially. 64 As the number of children prescribed
antidepressants grew, health professionals found throughout
57. Lieberman, supra note 9, at 7, 9; Thase, supra note 39.
58. See generally Carolina Cassels, FDA Approves New SNRI for Major
Depression, MEDSCAPE MEDICAL NEWS (July 26, 2013), http://www.medscape.
com/viewarticle/808481 (reporting on the fourth FDA-approved SNRI, Fetzima).
59. About Pristiq, PFIZER INC., http://www.pristiq.com/what-is-pristiq.aspx
(last visited Mar. 21, 2015); PRESCRIBING INFORMATION, PFIZER INC. (last
revised Sept. 2014), available at http://labeling.pfizer.com/showlabeling.aspx?
id=497.
60. Duloxetine (marketed as Cymbalta) Information, U.S. FOOD AND DRUG
ADMIN., http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm114966.htm (last updated Dec. 15, 2014).
61. DEP’T OF HEALTH AND HUMAN SERV., APPROVED DRUG PRODUCTS WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS: CUMULATIVE SUPPLEMENT 57
(2015), available at http://www.fda.gov/downloads/drugs/informationondrugs/
ucm086233.pdf.
See
also
PRESCRIBING
INFORMATION,
FOREST
PHARMACEUTICALS, INC. (last revised July 2014), available at http://www.frx.
com/pi/Fetzima_pi.pdf#page=1
[hereinafter
FETZIMA
PRESCRIBING
INFORMATION] (detailing the prescription information and medication guide for
those who are considering or already taking Fetzima).
62. Venlafaxine (marketed as Effexor) Information, U.S. FOOD AND DRUG
ADMIN., http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106481.htm (last visited Aug. 13, 2010).
63. Id. See generally Anil Nischal et al., Suicide and Antidepressants: What
Current Evidence Indicates, 10 MENS SANA MONOGRAPHS 33 (2012) (discussing
the possibility of antidepressants’ ability to increase the risk of suicide and
creating suicidal ideations); Charlotte Bjӧrkenstam et al., An Association
between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide – A
Nationwide Register-Based Case-Crossover Study, 8 PLOS ONE 1 (2013),
available
at
http://www.plosone.org/article/fetchObject.action?uri=info
%3Adoi%2F10.1371%2Fjournal.pone.0073973&representation=PDF (finding
“an overall increased risk of suicide during the first 28 days of initiation of SSRI
therapy”).
64. What are the Real Risks of Antidepressants?, HARV. HEALTH
PUBLICATIONS (June 9, 2009), http://www.health.harvard.edu/newsweek/
What_are_the_real_risks_of_antidepressants.htm
[hereinafter
HARVARD
HEALTH].
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various clinical trials that the risk of suicide doubled amongst
children, adolescents, and adults when taking an antidepressant. 65
The outcry from the public and Congress 66 led the FDA to create
harsher warnings for antidepressants and issue a news release in
October 2004 to the public and all pharmaceutical companies. 67 The
news release detailed the new FDA requirement for all
pharmaceutical companies to add a “black box” 68 label warning onto
their antidepressants concerning thoughts of suicide or suicide as a
potential side effect when taking the drug. 69 A black box label is the
strongest warning the FDA requires for prescription drugs that pose
substantial risks for “serious or life-threatening adverse effects, [as]
based on medical studies.” 70 Every antidepressant on the market
has this label on the box and in the medication guide giving
directions and information on the prescription drug.
65. Id.
66. HARVARD HEALTH, supra note 64.
67. FDA Statement on Recommendations of the Psychophamacologic Drugs
and Pediatric Advisory Committees, U.S. FOOD AND DRUG ADMIN. (Sept. 16,
2004),
http://www.fda.gov/newsevents/newsroom/pressannouncements/2004/
ucm108352.htm; FDA Launches a Multi-Pronged Strategy to Strengthen
Safeguards for Children Treated with Antidepressant Medications, U.S. FOOD
AND DRUG ADMIN. (Oct. 15, 2004), http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2004/ucm108363.htm. See also FDA Proposes New
Warnings about Suicidal Thinking, Behavior in Young Adults who take
Antidepressant Medications, U.S. FOOD AND DRUG ADMIN. (May 2, 2007),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm10
8905.htm [hereinafter FDA Proposes New Warnings], (proposing that all
antidepressants’ black box warnings be updated to “include warnings about
increased risks of suicidal thinking and behavior, known as suicidality, in young
adults ages 18 to 24 during initial treatment (generally the first one to two
months)”); John M. Grohol, The Black Box Warning – Antidepressants and the
Risk of Suicide, PSYCHCENTRAL, http://psychcentral.com/blog/archives/
2007/06/08/the-black-box-warning-antidepressants-and-the-risk-of-suicide/
(last visited Mar. 21, 2015) (arguing that although black box labels and
warnings are needed, much more in the way of publicity and press releases
needs to occur in order to have any effect in alerting consumers of the side
effects); see generally David Healy, Drug Regulation: Did Regulators Fail Over
Selective Serotonin Reuptake Inhibitors?, 333 BRITISH MEDICAL JOURNAL 92
(2006), available at http://www.bmj.com/content/333/7558/92 (discussing the
concern of antidepressant safety and how regulating agencies were slow to
present the data and risks associated with the drugs to the public).
68. A Guide to Drug Safety Terms at FDA, CONSUMER HEALTH
INFORMATION (U.S. Food and Drug Admin.), Nov. 2012, at 2, available at
http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ucm107976.p
df.
69. See U.S. FOOD AND DRUG ADMIN., CLASS SUICIDALITY LABELING
LANGUAGE FOR ANTIDEPRESSANTS AND MEDICATION GUIDE (2005), available at
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20031s045,20936
s020lbl.pdf.
70 Black Box Warning Resources, AMERICAN SOCIETY OF CONSULTANT
PHARMACISTS,
https://www.ascp.com/articles/black-box-warning-resources
(2015); Staff Writer, FDA Black Box Warnings, DRUGWATCH,
http://www.drugwatch.com/2012/01/18/fda-black-box-warnings/ (last modified
Nov. 19, 2014).
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Today, all six of the SSRIs, 71 all four of the SNRIs, 72 and all
other types of antidepressants 73 list suicidal ideation as a potential
side effect. The labels also include some mention of violence or
aggression that may be associated with taking the antidepressant. 74
But only Effexor lists a rare adverse event, homicide, on its label. 75
Effexor, manufactured by Wyeth Pharmaceuticals, Inc., received
FDA approval on December 28, 1993. 76 As noted above, Effexor was
71. As a reminder, the six SSRIs listed from above are Celexa, Lexapro,
Prozac, Luvox, Paxil, and Zoloft.
72. The four SNRIs listed from above are Pristiq, Cymbalta, Fetzima, and
Effexor.
73. Antidepressant Use in Children, Adolescents, and Adults, U.S. FOOD AND
DRUG
ADMIN.,
http://www.fda.gov/drugs/drugsafety/informationbydrug
class/ucm096273.htm (last updated Dec. 23, 2014).
74. U.S. FOOD AND DRUG ADMIN., CELEXA (CITRALOPRAM HYDROBROMIDE)
LABEL (2012), available at http://www.accessdata.fda.gov/drugsatfda_docs/
label/2012/020822s043lbl.pdf; U.S. FOOD AND DRUG ADMIN., LEXAPRO
(ESCITALOPRAM OXALATE) LABEL (2012), available at http://www.accessdata.
fda.gov/drugsatfda_docs/label/2012/021323s040lbl.pdf; U.S. FOOD AND DRUG
ADMIN., PROZAC (FLUOXETINE HYDROCHLORIDE) LABEL (2013), available at
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018936s100s101,02
1235s021lbl.pdf; U.S. FOOD AND DRUG ADMIN., LUVOX (FLUVOXAMINE
MALEATE) LABEL (2012), available at http://www.accessdata.fda.gov/drugs
atfda_docs/label/2012/021519s003lbl.pdf; U.S. FOOD AND DRUG ADMIN., PAXIL
(PAROXETINE HYDROCHLORIDE) LABEL (2012), available at http://www.
accessdata.fda.gov/drugsatfda_docs/label/2012/020031s067,020710s031.pdf;
U.S. FOOD AND DRUG ADMIN., ZOLOFT (SERTRALINE HYDROCHLORIDE) LABEL
(2013), available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/
019839s079,020990s038lbl.pdf; U.S. FOOD AND DRUG ADMIN., PRISTIQ
(DESVENLAFAXINE) LABEL (2013), available at http://www.accessdata.fda.gov/
drugsatfda_docs/label/2013/021992s033s036lbl.pdf; U.S. FOOD AND DRUG
ADMIN., CYMBALTA (DULOXETINE HYDROCHLORIDE) LABEL (2012), available at
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021427s040s041lbl.
pdf; U.S. FOOD AND DRUG ADMIN., FETZIMA PRESCRIBING INFORMATION, supra
note 61; U.S. FOOD AND DRUG ADMIN., EFFEXOR (VENLAFAXINE
HYDROCHLORIDE) LABEL (2012), available at http://www.accessdata.fda.gov/
drugsatfda_docs/label/2012/020151s031s055s058s060lbl.pdf
[hereinafter,
EFFEXOR LABEL]. See also Moore, supra note 25 (finding that violence as a side
effect of drugs has not been highly studied, and that eleven antidepressants
presented themselves as having highly disproportionately reported cases of
violence associated with their use); Peter R. Breggin, Suicidality, Violence and
Mania Caused by Selective Serotonin Reuptake Inhibitors (SSRIs): A Review
and Analysis, 16 INT’L J. RISK & SAFETY MED. 31 (2003/2004) (finding that
SSRIs are the common cause of “abnormal mental and behavioral conditions,”
spanning a spectrum from “mild agitation to manic psychoses, agitated
depression, obsessive preoccupations that are alien or uncharacteristic of the
individual, and akathisia”). See generally Maia Szalavitz, Top Ten Legal Drugs
Linked
to
Violence,
TIME
(Jan.
7,
2011),
http://healthland.time.com/2011/01/07/top-ten-legal-drugs-linked-to-violence/
(reporting that of the top ten drugs associated with violence, five were
antidepressants).
75. EFFEXOR LABEL, supra note 75. A “rare event” is classified as those
events that occur in less than one in 1000 patients. Id.
76. Effexor: Label and Approval History, U.S. FOOD AND DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=S
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required to put the mandatory suicide black box label warning in its
prescribing information and medicine guide. 77 However, unlike any
other antidepressant, Effexor lists “homicidal ideation.” 78
Homicidal ideation occurs when a person begins to have
thoughts of killing others and they imagine that homicide. Just as
suicidal ideation can occur and eventually lead to actual suicide, so,
too, can homicidal ideation occur and eventually lead to the death
of others. MediGuard.org and RxISK.org are prescription drugreporting websites where patients can disclose any side effect(s)
that they have experienced. 79 RxISK.org received one hundred and
thirty-three reports of homicidal ideation from taking venlafaxine 80
and forty-seven reports of venlafaxine as the suspected drug
associated with the homicide. 81 Although not highly conclusive by
any means, these reporting statistics show that homicide is
occurring when people take Effexor, and the drug, as the source of
causation for the heinous act, should not be disregarded.

C. Courts’ Responses to Defenses Attempted by Drugged
Defendants
Criminal defendants have many affirmative defenses available
to them. The facts of each case dictate which defenses are
appropriate. 82 Some defendants charged with homicide have argued
under a variety of affirmative defenses that antidepressant side
effects played a role in their conduct. Defendants have raised
defenses from insanity to impaired condition and even the infamous
earch.Label_ApprovalHistory#apphist (last updated Mar. 27, 2015).
77. EFFEXOR LABEL, supra note 74.
78. Id.
79. MEDIGUARD, supra note 16; About Us, RXISK, http://wp.rxisk.org/about/
(last visited Mar. 21, 2015).
80. Sixty-eight of the one hundred and thirty-three reports of homicidal
ideation were reported in the United States, with an additional thirty-eight
reports that did not specify the country in which the patient resided. Effexor
(Venalafaxine): Reported Side Effects – By Location: Homicidal Ideation (133
reported), RXISK, https://www.rxisk.org/Research/DrugInformation.aspx?Drug
ID=3181&ProductDrugID=594&ProductName=Effexor#11_10049666_0_0_1__
--__ (last visited Mar. 21, 2015).
81. Fifteen of the forty-seven reports were from the United States. Effexor
(Venalafaxine): Reported Side Effects – By Location: Homicide (47 reported),
RXISK, https://www.rxisk.org/Research/DrugInformation.aspx?DrugID=3181&
ProductDrugID=594&ProductName=Effexor#11_10020364_0_0_1__--__ (last
visited Mar. 21, 2015). See generally List of Some of the Cases of Homicides and
Attempted Homicides that have Occurred on SSRI, SNRI & Other
Antidepressants,
ADHD
Stimulants,
WHALE
(Apr.
19,
2007),
http://www.whale.to/a/homicidesSSRISandADHDmedications.pdf (listing a
myriad of different stories and criminal cases resulting from the association of
antidepressants and homicide, both attempted and successfully completed).
82. See generally Paul H. Robinson, Criminal Law Defenses: A Systematic
Analysis, 82 COLUM. L. REV. 199 (1982) (analyzing criminal law defenses
conceptually, and as the various defenses work as part of a larger system).
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“Zoloft Defense” 83 and “Prozac Defense.” 84 These arguments have
resulted in little success. But it remains unclear where courts stand
on the issue of antidepressants and the legal implications of their
heinous side effects. This is especially true when antidepressant
side effects are proffered as evidence during murder trials in
support of an affirmative defense or a sentence-mitigating factor.

III. ANALYSIS
This Part lays out the foundations of homicide and murder
within the American criminal law system. Then two plausible
affirmative defenses, involuntary intoxication and automatism, are
defined and analyzed. These two defenses are compared to
determine which will provide the best outcome at trial for a criminal
defendant whose adverse reaction to Effexor resulted in murder.

A. Homicide – A Basic Overview
In the United States criminal law system, most offenses have
both an actus reus element (the act) and a mens rea element (the
mental state). 85 In order to find someone culpable, both of these
elements must be present. 86 When analyzing potential defenses for
homicide and murder while taking an antidepressant, the mens rea
element is critical to focus on and center the defense around. Most
likely the actus reus is not disputed as the defendant did perform
an action that resulted in the death of someone. Because finding
culpability for defendants who had an adverse reaction to their
83. See State v. Pittman, 647 S.E.2d 144, 167, 170–71 (S.C. 2007) (holding
“the defense’s argument that the ingestion of Zoloft qualifies as a lawful act in
the context of an involuntary manslaughter charge to be unconvincing,” and
holding that the trial court properly instructed the jury in applying the
M’Naughten test for the involuntary intoxication defense). In the jury trial of
Christopher Pittman, the defense presented a manual that Pfizer gives to
prosecutors when Zoloft is under fire in litigation, just as in cases like Pittman’s,
to ultimately snuff out the entire defense. Rob Waters, Prosecuting for Pharma:
Antidepressant Manufacturers Team up with District Attorneys to Make Sure
the Zoloft Defense Doesn’t Fly, MOTHER JONES (Nov./Dec. 2004)
http://www.motherjones.com/politics/2004/11/prosecuting-pharma.
See
PFIZER’S ZOLOFT LITIGATION MANUAL (Feb. 7, 2005), available at http://health
wyze.org/archive/zoloft_defense_manual.pdf (providing an easily accessible
copy of Pfizer’s Zoloft Litigation Manual used as an exhibit by the defense in
Christopher Pittman’s murder trial).
84. See Harris, supra note 15, at 378–81 (finding the viability of using Prozac
as an excuse for criminal conduct by way of a legal affirmative defense to be
lacking any success in court precedent); Catherine M. Vale, Notes and
Comments, The Rise and Fall of Prozac: Products Liability Cases and “The
Prozac Defense” in Criminal Litigation, 12 ST. LOUIS U. PUB. L. REV. 525, 544–
47 (1993) (discussing the rise of the “Prozac Defense” in criminal litigation and
noting that juries have not been easily persuaded by its use).
85. Id.
86. Id.
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antidepressant, namely Effexor, will rely upon a determination of
the defendant’s mental state, affirmative defenses that negate or
prove that the defendant lacked a conscious mental state at the time
will provide better success.
Any person in modern American society with access to basic
cable, a news source, or a social media platform has heard the terms
“homicide,” 87 “murder,” 88 and “manslaughter.” 89 Understanding
these terms and their legal implications is important to this
Comment’s analysis and proposal. 90 “Homicide” is the taking of a
person’s life by another when there is no justification for doing so. 91
“Manslaughter” 92 covers both voluntarily or involuntarily
homicides where the actor often can justify or explain the taking of
that life, such as when a person acts out in the “heat of the moment”
or when someone is mentally insane. 93 Manslaughter lacks the
malice aforethought found in murder charges. “Murder” involves a
malicious mental state where the actor intends to take another’s life
either by knowing their actions will lead to a person’s death or

87. JOSHUA DRESSLER, UNDERSTANDING CRIMINAL LAW 498 (5th ed. 2009).
88. The common law has long recognized murder as “the killing of a human
being by another human being with malice aforethought.” Id. The key to
distinguishing murder from other killings, like suicide, once included in the
early common law form of homicide, and manslaughter, was the notion of
malice. United States v. Wharton, 433 F.2d 451, 454 (D.C. Cir. 1970);
DRESSLER, supra note 87, at 495, 498. Malice has long been recognized as a
person’s total disregard for human life and its value, as it manifests in the
person’s mental state resulting in death. Id. at 499; Wharton, 433 F. 2d at 456.
89. Manslaughter exists in a middle ground between the malice needed to
define murder and those killings done with justification or excuse, as it still
constitutes an unlawful killing. DRESSLER, supra note 87, at 499 n.33.
Generally, manslaughter is then broken down into two types. The first type,
voluntary manslaughter, is committed when a killing is intentional but arises
out of the “sudden heat of passion” most commonly by provocation. Id. at 500.
The second, involuntary manslaughter, occurs when a lawful act is done in an
unlawful manner and results from criminal negligence, or when the commission
of an unlawful act, that is not a felony, results in the loss of life (like a lesser
version of felony murder). Id.
90. Stephen J. Morse, Criminal Law: Undiminished Confusion in
Diminished Capacity, 75 J. CRIM. L. & CRIMINOLOGY 1, 6 (1984).
91. DRESSLER, supra note 87, at 498. See, e.g., MODEL PENAL CODE § 210.1
(West 2014) (defining [criminal] homicide as “murder, manslaughter, or
negligent homicide” to include all situations in which a person “purposely,
knowingly, recklessly, or negligently causes the death of another human
being.”).
92. The Model Penal Code defines manslaughter as actions that cause death
to another when “committed recklessly.” MODEL PENAL CODE § 210.3(1)(a).
93. DRESSLER, supra note 87, at 495, 498, 499–500. For example, the Model
Penal Code provides that “a homicide which would otherwise be murder [that]
is committed under the influence of extreme mental or emotional disturbance
for which there is reasonable explanation or excuse” is considered
manslaughter. MODEL PENAL CODE § 210.3(1)(b). “The reasonableness of such
explanation or excuse shall be determined from the viewpoint of a person in the
actor’s situation under the circumstances as he believes them to be.” Id.
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purposefully taking that person’s life. 94
To establish that a defendant committed murder, the
prosecution must prove, beyond a reasonable doubt, that the
defendant had a specific intent to kill. 95 Trying to prove intent,
which is inherently subjective, places a substantial demand on the
prosecution. 96 Thus, the law 97 permits prosecutors to satisfy this
burden by demonstrating that the defendant only intended to inflict
“grievous bodily injury” but actually caused death. 98 If the
prosecution cannot prove one of those elements, the defendant is
“not blameworthy” for that crime and to punish him would truly be
“unjust as well as unconstitutional.” 99 Criminal defendants who
murder someone while taking antidepressants is the focus of this
Comment and will be used to analyze two possible affirmative
defenses. 100
94. The Model Penal Code defines murder as causing the death of another
“purposely or knowingly; or . . . under circumstances manifesting extreme
indifference to the value of human life.” Id. § 210.2(1). Many states break down
the criminal offense of “murder” into “degrees.” See, e.g., COLO. REV. STAT. § 183-101 et seq. (1995) (classifying Colorado murders into two degrees); 720 ILL.
COMP. STAT. 5/9-1 et seq. (2011) (classifying Illinois murders into two degrees);
CAL. PENAL CODE § 187 et seq. (classifying California murders into two degrees).
These classifications seek to apply statutorily mandated sentence ranges and to
punish the higher classification, first degree murder, in a harsher fashion than
the lower, such as second degree murder and even third degree in other states.
See, e.g., COLO. REV. STAT. § 18-1.3-401 (West 2015) (mandating a presumptive
sentence of life imprisonment or death for first degree murders and only eight
to twelve years for second degree murder); CAL. PENAL CODE § 190 (2000)
(mandating an additional 10 year sentencing enhancement for first degree
murder); 720 ILL. COMP. STAT. 5/9-1 (mandating a death sentence for first
degree murders). DRESSLER, supra note 87, at 501. This is known as the
Pennsylvania Model of murder, as was created in the reformation of criminal
laws in the late eighteenth century. Id. at 500. States that do not follow this
model most likely frame their statutes around the Model Penal Code, which
does not use “degrees” or the malice aforethought, as it is subsumed by the
extreme recklessness of the actor. Id. at 537.
95. DRESSLER, supra note 87, at 503.
96. A syllogism is used to break down the mental state of the defendant in
order to show the burden is met when the prosecution establishes “(1) ordinary
people intend the natural and probable (or “foreseeable”) consequences of their
actions; (2) the defendant is an ordinary person; and (3) therefore, she intended
the natural and probable consequences of her actions.” Id. at 502.
97. As a clarifying note, this Comment uses the Modern Penal Code as the
basis for much of its analysis. Statutes will vary state to state, so the analysis
given here is in very general terms.
98. DRESSLER, supra note 87, at 507. In Illinois for example, a defendant
may be found guilty of murder without having a specific intent to kill if the
defendant acts in way that “create[s] a strong probability of death or great
bodily harm to that individual or another” or causes a death while “attempting
or committing a forcible felony other than second degree murder.” 720 ILL.
COMP. STAT. 5 § 5/9-1(a)(2)–(3).
99. Morse, supra note 90, at 6.
100. The focus on murder for this Comment is because the crime requires a
specific intent. A person commits murder when they have a knowing
recklessness and disregard for another’s life, or they know that their actions
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B. Involuntary Intoxication Defense: Served Neat or on
the Rocks?
When homicide results from the use of popular drugs and their
adverse effects, 101 involuntary intoxication warrants discussion as
a potential defense. 102 To be considered “intoxicated,” a person must
have ingested a substance that causes a “disturbance of [their]
mental or physical capacities.” 103 An involuntary intoxication
narrows the definition even further. 104 Courts limit this defense to
instances where a person: (1) is coerced into taking the substance;
(2) ingests the substance by an innocent mistake; (3) is prescribed a
medication and becomes unexpectedly intoxicated; or (4) suffers a
“pathological intoxication.” 105 Proving any one of these four
instances of intoxication is difficult and highly burdensome on the
defendant, which ultimately leads to the involuntary intoxication
defense rarely finding success. When a defendant presents this
defense, she acknowledges committing the illegal act. 106 At the
same time, though, the defendant argues she lacked the required
mental state. 107 This is because she was intoxicated and thus could
not form the specific intent needed to commit murder. 108
will result in death. DRESSLER, supra note 87, at 510. In contrast, someone who
should be aware that his or her actions could result in death, but ultimately the
person lacks the intentional malice element, commits manslaughter. Id.
Additionally, murder will be analyzed as a general concept without breaking
down the concept into the different degrees of murder; i.e., first or second.
101. See SSRI Stories, supra note 24; RXISK, supra note 21.
102. DRESSLER, supra note 87, at 328.
103. People v. Low, 732 P.2d 622, 627 (Colo. 1987). This statutory definition
in Colorado is based upon the Model Penal Code’s definition. MODEL PENAL
CODE § 2.08(5)(a). The law generally does not distinguish between alcohol,
drugs, or other substances that can intoxicate a person. DRESSLER, supra note
87, at 317.
104. DRESSLER, supra note 87, at 328.
105. Id. at 328–29. See City of Minneapolis v. Altimus, 238 N.W.2d 851, 855
(Minn. 1976) (quoting the Model Penal Code section 2.08(5)(c) in its application
of the involuntary intoxication defense). A “pathological intoxication” occurs
where a person is susceptible to an exaggerated reaction from the substance
taken and they are unaware of this substantial effect, and generally this occurs
as a result of a pre-existing mental or physical condition. DRESSLER, supra note
87, at 329. Most often this occurs when a person drinks the smallest bit of
alcohol but responds in a very aggressive and violent way. See generally Tim
Feulner, Note, The Minotaur Defense: The Myth of the Pathological Intoxication
Defense, 49 AM. CRIM. L. REV. 1969 (2012) (demonstrating the use of a
pathological intoxication defense, as well as its natural incorporation into other
involuntary act defenses).
106. DRESSLER, supra note 87, at 328. This satisfies the actus reus element.
Id.
107. Id. This does not satisfy the mens rea element. Id.
108. Id. It is also important to note that under the Model Penal Code, there
is no distinction between “general” and “specific” intent crimes, and the defense
just goes towards whether the person had the required mental state for the
offense. MODEL PENAL CODE § 2.08(1).
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Since 1915, the federal courts have faced claims of involuntary
intoxication from defendants who took prescription drugs and the
courts have harshly criticized the defense. 109 In Perkins v. United
States, the Fourth Circuit found there is no onus on a patient to
“know that a physician’s prescription may produce a dangerous
frenzy.” 110 The court reasoned that if such a frenzied effect occurred
by taking the medicine as instructed by his physician, but then he
“was thrown into a mental state which placed him beyond his own
control . . . he would not be legally responsible.” 111 For the first time,
the court created and recognized the third instance of involuntary
intoxication listed above, where a person is prescribed a medication
and then unexpectedly becomes intoxicated because of that drug.
In 1976, the Minnesota Supreme Court gave involuntary
intoxication even stronger footing in Minneapolis v. Altimus. 112 The
Altimus Court created a more readily understandable set of
elements to determine whether a defendant should be criminally
culpable for her actions. 113 First, the defendant “must not know, or
have reason to know, that the prescribed drug is likely to have an
intoxicating effect.” 114 Second, the prescribed drug must have
caused her to be intoxicated during the alleged criminal act. 115
Third, that involuntary intoxication must have rendered her
temporarily insane. 116 This analysis strengthens courts’ recognition
109. DRESSLER, supra note 87, at 328; Perkins v. United States, 228 F. 408
(4th Cir. 1915). See also Mitchell Keiter, Just Say No Excuse: The Rise and Fall
of the Intoxication Defense, 87 J. CRIM. L. & CRIMINOLOGY 482, 482–83; 484–92
(1997) (offering an overview of why courts and society have had differing and
changing opinions on intoxicated defendants over the decades).
110. Id. at 415.
111. Id. at 416.
112. Altimus, 238 N.W.2d at 856–57. In this case, the defendant was arguing
that because he took Valium, as prescribed by his physician for a back problem
and the flu only three days prior, “he was unexpectedly intoxicated to the point
of unconsciousness, incapable of controlling his actions” when he crashed into
another vehicle and fled the accident scene, and he should not be held criminally
responsible. Id. at 853–54, 857.
113. Id. at 857.
114. Id. If the defendant was warned of such extreme side effects, or it could
be demonstrated that he read the prescription or should have known of the
effects, then the inquiry into whether the involuntary intoxication defense
satisfied the elements would fail. Id.
115. Id.
116. Id. Here is another area of great contention amongst courts when
determining if involuntary intoxication ought to be distinct from an insanity
defense, or perhaps that it is one in the same family of defenses. See generally
Feulner, supra note 105, at 1983–86 (arguing involuntary intoxication as a mens
rea defense, which would mean it is not an affirmative defense but another form
of evidence that shows the prosecution failed to meet their burden on the mens
rea element, like with insanity); Deborah W. Denno, Crime and Consciousness:
Science and Involuntary Acts, 87 MINN. L. REV. 269, 337–345 (2002) (comparing
an involuntary unconsciousness defense to an insanity defense in its application
and in the viewpoint of courts); Robinson, supra note 82, at 221–29 (setting forth
a five-tiered framework from which courts can conceptualize the different types
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of involuntary intoxication as a complete defense by outlining the
elements needed to prove the defense in a way that defendants can
attempt to present it successfully. 117 This framework for
involuntary intoxication elements can be applied to any jurisdiction
where involuntary intoxication is allowed as an affirmative defense,
as most jurisdictions will require the defendant to show that they
had no reason to know or believe that the prescribed drug would
have such an adverse effect and that the adverse effect is what led
to the murder.
The United States Supreme Court has not offered an opinion
on whether involuntary intoxication is a viable defense. 118 However,
in a dissent to a decision regarding voluntary intoxication in
Montana v. Egelhoff, Justice Sandra Day O’Connor, joined by
Justices John Stevens, David Souter and Stephen Breyer, discuss
how Montana’s statute carving out an exception to involuntary
intoxication evidence. 119 The dissenting Justices assert that state
legislatures cannot preclude a defendant from presenting evidence
of involuntary intoxication to rebut the prosecution’s case because
such evidence goes to the heart of the mental state of the defendant
and is thus relevant. 120 The Court acknowledged that the state has
a significant interest in protecting the public by ensuring through
its criminal laws that a defendant is not acquitted of heinous acts
because she voluntarily become intoxicated. 121 As the dissents of
of defenses and allowing the defenses to be more properly and consistently
applied in the criminal law context). The Minnesota Supreme Court held that
“if the defendant is mentally deficient due to involuntary intoxication, then he
may be excused from criminal responsibility” only if that finding of temporary
insanity satisfied its statute per the third element outlined in the case. Altimus,
238 N.W.2d at 857.
117. Legislatures will go even further to codify the defense as a complete
defense, acquitting culpability entirely, and the Supreme Court has not ruled
against such statutes. See Hendershott v. People, 653 P.2d 385, 396 n.10 (Colo.
1982), cert. denied, 459 U.S. 1225 (1983). See also Keiter, supra note 109, at
518–20 (providing an appendix of states and how they apply intoxication
defenses towards various crimes, as of 1997, for a general idea of where the
states stand).
118. However, the Supreme Court has granted petitions for writ of certiorari
and decided three cases dealing with voluntary intoxication. See generally
Montana v. Egelhoff, 518 U.S. 37 (1996) (holding that a jury instruction telling
the jurors to disregard the intoxicated state of the defendant was not a violation
of defendant’s Due Process rights); Tucker v. United States, 151 U.S. 164 (1894)
(finding that voluntary intoxication does not in any way excuse crimes
committed while effected); Hopt v. People, 104 U.S. 631 (1881) (holding that
evidence of defendant’s intoxication at the time of the murder was admissible).
119. Montana v. Egelhoff, 518 U.S. 37, 67 (1996) (O’Connor, J., dissenting).
120. Here, the Supreme Court decided that in this particular case where a
man shot two people while voluntarily intoxicated, states may create statutes
that limit the introduction of such evidence, as criminal law is left for the states
to dictate. Id. at 56. See also Keiter, supra note 109, at 500–05 (explaining the
holding of Egelhoff and the implications that it created for defendants arguing
an intoxication defense).
121. Id. at 56.
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both Montana v. Egelhoff and Begay v. United States note, many
states do recognize involuntary intoxication as a defense. 122
Involuntary intoxication is an easy vehicle for those defendants
arguing the infamous “Prozac defense” and its other well-known
antidepressant counterparts. 123 The viability of this defense has yet
to be persuasive in criminal trials. 124 Employing the elements as
laid out in Altimus, a defendant today would have a particularly
hard time proving the last element. 125 The third element requires
the prescription drug have an unknown effect that renders the
defendant temporarily insane at the time of the act’s commission. 126
In State v. Gardner, a defendant almost successfully utilized
the involuntary intoxication defense in a murder case involving
consumption of a prescription drug. 127 During pre-trial preparation,
the defendant told the prosecution he would raise the involuntary
intoxication defense because he consumed Prozac. 128 This revelation
prompted the prosecution to file a pre-trial motion to determine
which legal standard would be used for this defense. 129 Utah did not
have a statute specifically for involuntary intoxication. 130
Therefore, the trial court held the defendant would have to argue
under a mental illness defense. 131 Under this defense, the defendant
would have to show that he was mentally ill at the time of the
murder, and due to that mental illness, he did not have the requisite
mental state to have committed murder. If that defense could be
met, he would be found not guilty. 132 Ultimately, the Utah Supreme
Court affirmed, holding that involuntary intoxication should not be
considered any differently than a defense of mental illness. 133
122. Id. at 67; Begay v. United States, 553 U.S. 137 (2008). In Begay, the
dissenting opinion by Justice Samuel Alito, and joined by Justices David Souter
and Clarence Thomas, noted the troublesome nature of statutes that have
judicially added requirements, such as “purposeful” in Georgia, that would
require a defendant to prove they intended to drive in driving under the
influence or while intoxicated cases. Id. at 159 (Alito, J., dissenting).
123. Harris, supra note 15, at 378–81; Vale, supra note 84, at 544–47.
124. Meghan P. Ingle, Note, Law on the Rocks: The Intoxication Defenses are
Being Eighty-Sixed, 55 VAND. L. REV. 607 (2002). See Harris, supra note 15, at
380 (finding that up until the comment’s publication in 1999, no “Prozac patient
[had] met the legal definition of insanity.”).
125. “The third requirement is that the defendant, due to involuntary
intoxication, is temporarily insane.” Altimus, 238 N.W.2d at 857.
126. Harris, supra note 15, at 380.
127. State v. Gardner, 870 P.2d 900 (Utah 1993).
128. Id. at 900.
129. Id. at 900–01.
130. Id.
131. Id. at 900–02.
132. Id.
133. Id. at 902. This has remained the standard followed by other states
with similar statutory provisions, as seen in the line of cases that cited to the
Gardner decision in Utah. See State v. McKeon, 38 P.3d 1236 (Ariz. App. 2002)
(analyzing the prescription medicine involuntary intoxication defense for when
a defendant takes a drug that is psychoactive and whether or not it is then
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Involuntary intoxication seems like a logical defense for a
defendant who suffered an adverse reaction to a prescribed
antidepressant. As the defendant knew they were ingesting a drug
that is meant to have a positive effect, the adverse reaction of
murder would not be foreseeable to them. There is a high probability
that patients who are prescribed the drug Effexor, specifically, are
not warned that homicidal ideation might occur. However, the
current view of the courts indicates the chances of successfully
asserting the involuntary intoxication defense are very low.

C. Automatism Defense: Domō Arigatō, Your Honor 134
Luckily, another defense offers potential success for a
defendant accused of committing murder while on a prescription
antidepressant. 135 The second defense is the automatism defense. 136
A person is in a state of automatism when they are able to perform
actions but are unconscious of their conduct, or acting without the
requisite will. 137 As early as 1879, state courts recognized that a
defendant should not be punished for actions done in an
unconscious state. 138 Especially where a defendant does not have
prior knowledge that such an unconscious state will or can occur. 139
California is one state that recognizes automatism as a complete
defense, even for criminal homicide. 140 The California Appellate
Court in People v. Newton reasoned that when a person is
involuntarily unconscious, 141 it does not always manifest in the
abused through a statutory lens); Brancaccio v. State, 698 So. 2d 597 (Fla. App.
1997) (recognizing that involuntary intoxication instructions should be given at
the trial court level and not just recognized on appeal).
134. Domō Arigatō means “thank you” in Japanese. Arigatō,
DICTIONARY.COM, http://dictionary.reference.com/browse/arigato (last visited
Mar. 27, 2015).
135. Both the involuntary intoxication and automatism defenses deal with
negating the requisite mental state needed in order to be convicted of murder.
DRESSLER, supra note 87, at 328–31; Emily Grant, Note, While You were
Sleeping or Addicted: A Suggested Expansion of the Automatism Doctrine to
Include an Addiction Defense, 2000 U. ILL. L. REV. 997, 1003 (2000). See State
v. Rogers, 725 S.E.2d 342, 349 (N.C. Ct. App. 2011) (holding in North Carolina
that automatism is an affirmative defense that negates both the mental state
and voluntary act elements to a criminal charge).
136. 2 PAUL H. ROBINSON, CRIM. L. DEF. § 172 (2013).
137. People v. Grant, 360 N.E.2d 809, 814 (Ill. App. Ct. 1977); Fulcher v.
State, 633 P.2d 142, 145 (Wyo. 1981); BLACK’S LAW DICTIONARY 154 (9th ed.
2009).
138. See Fain v. Commonwealth, 78 Ky. 183 (Ky. App. Ct. 1879) (finding that
where the prisoner was awoken from sleep, and then shot and killed the person
who awoke him, he could not be held legally culpable for being unconscious
during the act because of his lack of knowledge for this propensity of violence at
such a moment).
139. Id.
140. People v. Newton, 8 Cal. App. 3d 359, 376 (Cal. App. 1970).
141. They are involuntarily unconscious not because of an act they have
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physical ways that people often expect, like being in a coma. 142
The Montana Supreme Court recently addressed the
automatism defense for the first time in City of Missoula v.
Paffhausen. 143 The defendant was a young woman charged with
driving under the influence. 144 She argued that because she was
slipped a date rape drug, she was unable to knowingly and
voluntarily commit the act of driving while under the influence. 145
The Montana Supreme Court held that allowing the defendant to
argue the automatism defense was statutorily allowed, and the
“absolute liability” element of a DUI is not, in fact, wholly
absolute. 146 The court further outlined that it is up to the defendant
to prove through admissible evidence of her state of automatism at
the time, and that the burden to prove each and every element,
beyond a reasonable doubt, still included that of the defendant’s
voluntary act. 147
The automatism defense differs from other mental illnesses or
insanity defenses because automatism does not require a prior
mental disease or defect. 148 Automatism only requires the person
acted without any volition. 149 Asserting the automatism defense
means the prosecution cannot prove the actus reus, because the
defendant was not acting voluntarily. 150 Defendants can have a
difficult time proving that what put them in a state of automatism
was not voluntary. 151 This presents a sizable hurdle for defendants
done or a voluntary intoxication. Id.
142. Id.
143. City of Missoula v. Paffhausen, 289 P.3d 141 (Mont. 2012).
144. Id. at 144.
145. The defendant argues this particular crime from the actus reus
standpoint because DUI is an absolute liability offense and her mental state
would not be addressed per the Montana statutes. Id. at 145.
146. Id. at 147.
147. Id. at 148. The DUI offense is to be distinguished from homicide because
a finding for murder requires the mental state be proven, whereas DUI does
not. Id. at 145; DRESSLER, supra note 87, at 537.
148. Grant, supra note 135, at 1000–04.
149. Id. Also important to note is the difference in treatment between a
defendant who is found legally insane and a defendant who successfully argues
an automatism defense. Id. at 1004–05. If a defendant is found insane, they will
be sentenced to a mental institution, whereas someone who suffers from a state
of automatism, like the akathisia associated with taking prescription drugs,
there is no long-term cure needed to assist the defendant. Id.; Akathisia,
Medical,
MERRIAM-WEBSTER
DICTIONARY
http://www.merriamwebster.com/medical/akathisia (last visited Mar. 27, 2015). “Akathisia” is a
“condition characterized by uncontrollable motor restlessness.” Id.
150. Feulner, supra note 105, at 1986–87. See generally ROBINSON, supra
note 131, at § 171 (discussing the objective and subjective duality of the
“voluntary act” requirement of culpability in nearly all offenses).
151. See generally Eunice A. Eichelberger, Annotation, Automatism or
Unconsciousness as Defense to Criminal Charge, 27 A.L.R.4th 607 (2013) (listing
a variety of cases throughout the United States where defendants have
unsuccessfully argued an automatism defense because the drugs that affected
them were taken voluntarily or with knowledge of the effects the drug would
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taking an antidepressant and then committing murder. 152 The
prosecution will contend that the defendant voluntarily took the
antidepressant. Furthermore, the prosecution will insist that not
knowing the side effects of the antidepressant should make the
defendant accountable and culpable for the murder. Conversely, the
defendant will argue they did not know the extreme effects and
heinous adverse events that would result from taking the drug. 153
Not every state will find the automatism defense to wholly excuse
the defendant’s actions but will allow for the argument of the
unconscious state to be considered during sentencing as a
mitigation factor.
Arguing the automatism defense gives the defendant an actual
chance of success at trial. They will not have to prove any prior
medical conditions, or that they temporarily became insane, a
highly burdensome and difficult element to establish. Additionally,
defendants asserting the automatism defense have modern science
at their disposal to make the defense more compelling, as presented
in my proposal. This defense will allow the defendant to
acknowledge that they took the antidepressant, namely Effexor,
and then became involuntarily unconscious due to an adverse side
effect of the drug. During that state of unconsciousness the murder
takes place and therefore the defendant was not in the conscious
state to have willingly acted in such a heinous way. A defendant
asserting the automatism defense will have a better opportunity to
present a compelling defense that can help establish their innocence
than with the impossible, uphill battle of involuntary intoxication.

IV. PROPOSAL
The automatism defense allows defendants an opportunity to
present a viable defense for homicide in instances of
sleepwalking. 154 Likewise, courts should also recognize this defense
for instances where a defendant, while taking Effexor, commits

have on the defendant).
152. Id.
153. The entire premise of this defense, for the purpose of this Comment, is
that defendants did not know of the side effects that either allegedly or
ultimately led to the homicide. As such, a best practice is not to just have the
FDA put black box label warnings on the drugs, but to also put a duty upon
doctors to make sure they are informing patients of all potential side effects,
including homicidal ideation for those taking Effexor, as under the assumption
that doctors are aware of all the side effects from the manufacturing companies.
Grohol, supra note 67; Cohan, supra note 15, at 128.
154. Grant, supra note 135, at 997.
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murder. 155 Blood 156 or genetic testing 157 for mutations on the
CYP450 gene 158 can prevent future homicides by identifying people
who are predisposed to side effects from these drugs. 159 In those
jurisdictions where automatism is not accepted by courts as a
complete defense, the developments in science should be taken into
consideration as a substantial mitigating factor in sentencing.

A. Who Should Be Able to Successfully Argue an
Automatism Defense for Antidepressant-Induced
Murder?
In 2003, public concern and push from the science and medical
fields led the FDA to recognize that antidepressants caused heinous
side effects. 160 However, the only antidepressant given a black box
warning for homicide and homicidal ideations in the United States
was, and remains, Effexor. 161 As the sole antidepressant warning of
155. See generally Michele Tuminello et al., The Phenomenology of
Specialization of Criminal Suspects, 8 PLOS ONE 1, 1 (2013), available at
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.00647
03 (explaining how research over the past couple of decades has shown theories
emerging to demonstrate, and perhaps prove, that genetic and social factors can
lead to violence, particularly in the relationship between the brain and that
person’s pre-existing propensity towards violence and delinquency).
156. See Kate Kelland, Study Finds Why Antidepressants Work Better for
Some, REUTERS (Sep. 19, 2012), http://www.reuters.com/article/2012/09/19/usdepression-drugs-biomarkers-idUSBRE88I0RL20120919 (finding in a new,
small study in England, that high levels of inflammation in biological markers
can be identified in the blood to help “personalize the treatment of depression”
and help remove the “trial and error” approach taken by most prescribing
physicians when putting their patients on an antidepressant).
157. See generally Julie Steenhuysen, Getting Personal: New Tests Aid Drug
Performance, REUTERS (July 30, 2009), http://www.reuters.com/article/
2009/07/31/us-diagnostics-drugs-idUSTRE56T79P20090731 (explaining how
the 2003 Human Genome Project lead to an exploration of biomarkers, such as
proteins or genes, to identify which drugs will work best for certain people,
depending upon their biological make-up, as the push from regulators like the
Food and Drug Administration goes towards requiring more drug companies to
use “companion diagnostic tests” before a patient participates in a clinical trial
or uses the drug).
158. See generally Yolande Lucire & Christopher Crotty, AntidepressantInduced Akathisia-Related Homicides Associated with Diminishing Mutations
in Metabolizing Genes of the CYP450 Family, 4 PHARMACOGENOMICS &
PERSONALIZED MED. 65 (2011) http://www.dovepress.com/antidepressantinduced-akathisia-related-homicides-associated-with-dim-peer-reviewedarticle-PGPM (finding that many of the drugs used to chemically alter the brain,
like SSRIs and SNRIs do with seratonin, interact with the cytochrome 450
(CYP450) “superfamily of genes,” which is a genetically determined system of
enzymes that are crucial to metabolizing antidepressants and many other drugs
commonly prescribed).
159. EFFEXOR LABEL, supra note 74.
160. FDA Proposes New Warnings, supra note 67; Grohol, supra note 67.
161. EFFEXOR LABEL, supra note 73.
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homicidal ideation, the automatism defense should be available to
those defendants that are prescribed and taking Effexor at the time
of the murder. 162 When a person takes Effexor, they are not
rendered mentally insane, nor are they involuntarily intoxicated.
They are put into a state of unconsciousness because their body is
not properly digesting the drug. This affects them in a seriously
adverse way that is warned about on the black box label for Effexor.
Yet no precautions are taken to make sure a person is not
predisposed to suffer that rare, yet occurring, adverse event of
homicidal ideation.
Even more so, this defense should be available for Effexor users
who have no history of mental illness or violence. A criminal
defendant, who shows that they were prescribed Effexor, and they
were taking the antidepressant at the time of the murder, or
recently stopped before the murder, 163 should be entitled to
presenting this defense. In a jury trial, the automatism defense can
help the defendant put forth a story that allows the jury to wrap
their minds around how something so heinous could occur by
someone that does not fit the murderer mold. So often juries want
to hear from the defendant and understand why the defendant
would do such a thing to someone else. The automatism defense not
only allows an opportunity for the defendant to explain how or why
they murdered that person, ultimately because of taking Effexor
and having an adverse reaction to the drug, but also it allows the
jury to satisfy their need to know and hear the defendant’s side of
the story.

B. What Can Prove the Drugs Induced the Murder?
There are existing biomarkers that tell physicians which drugs
a person can or cannot properly digest in their bodies. 164 Science
162. Important to note that often people are on a “cocktail” of drugs and not
just the one antidepressant when the murder occurs. See Lucire, supra note 146,
at 71–76 (detailing ten subjects who committed homicide while on an
antidepressant and studied for this research article); SSRI Stories, supra note
24 (providing numerous stories of those affected by antidepressants in
combination with other prescription drugs). As well, people are sometimes
switched from one type of antidepressant to another when the adverse event
happens, only a matter of days to weeks after the switch is made. Lucire, supra
note 146; SSRI Stories, supra note 24.
163. Adverse side effects are also experienced when people stop taking the
antidepressant and their bodies can then go through withdrawal symptoms that
lead to the adverse events on the warning labels. Cohan, supra note 15, at 128–
30. See generally Rebecca White, Waking Up from Sadness: Many Find Trouble
Getting off Antidepressants, AL JAZEERA AM. (Jan. 22, 2014),
http://america.aljazeera.com/articles/2014/1/22/patients-mostly-womenfindtrou
blegettingoffofantidepressants.html (reporting on the negative side effects
antidepressant users can suffer when they stop taking the drug, of which
women make up a substantial number of the affected).
164. Kelland, supra note 156; Steenhuysen, supra note 157; Lucire, supra
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proving that the criminal defendant suffered from an adverse
reaction to the antidepressant exists. 165 Cytochrome P450 (CYP450)
is the family of genes responsible for creating the enzymes essential
to digest and breakdown antidepressants. 166 When there is a genetic
mutation on any of the four alleles of this gene, that person’s body
is unable to produce the enzymes needed to digest the drug. 167 This
results in a toxic buildup of the antidepressant in the targeted area
for the medication, the brain. 168 For those taking antidepressants,
this knowledge can be a matter of life or death.
A body’s inability to break down the antidepressant properly
causes a toxic buildup in the brain. 169 This buildup can lead to
actions arising out of an unconscious mental state because the drugs
are not properly digested and in return affect that person in an
adverse way that does not result as intended to suppress the

note 158.
165. Lucire, supra note 158, at 68–71. See also K. Oved et al., Genome-wide
Expression Profiling of Human Lymphoblastoid Cell Lines Implicates Intergrin
Beta-3 in the Mode of Action of Antidepressants, 3 TRANSLATIONAL PSYCHIATRY
1 (2013) (studying human genome expressions to figure out why SSRIs do not
have immediate effects on some patients, and if any genomic expressions have
a link to any activity in the serotonin transporter).
166. Lucire, supra note 158. See generally PK Gillman, Tricyclic
Antidepressant Pharmacology and Therapeutic Drug Interactions Updated, 151
BRIT. J. PHARMACOLOGY 737, 737–48 (2007), available at http://www.ncbi.
nlm.nih.gov/pmc/articles/PMC2014120/pdf/0707253a.pdf (finding as science
advances, the importance of noting the interactions of enzymes and receptors to
antidepressants and other drugs allows for a greater understanding of the
effects the drugs can have on the human body). There exists an entire online
database concerning the CYP450 allele nomenclature with useful links and
charts to better understand how CYP450 interacts with drugs. The Human
Cytochrome P450 (CYP) Allele Nomenclature Database, CYPALLELES,
http://www.cypalleles.ki.se/index.htm (last visited Mar. 21, 2015).
167. Lucire, supra note 158.
168. Id.; Gillman, supra note 169; Breggin, supra note 74, at 35–36.
169. See Bhawana Arora & Nirupama Kannikeswaran, The Serotonin
Syndrome–The Need for Physician’s Awareness, 3 INT. J. EMERGENCY MED. 373,
374 (2010) (finding that serotonin syndrome is often in patients taking
antidepressants and “occurs due to excess serotonin activity in the brain and
periphery”); see also Peter Breggin, Intoxication Anosognosia: The Spellbinding
Effect of Psychiatric Drugs, 8 ETHICAL HUMAN PSYCHOLOGY & PSYCHIATRY 201,
205–206, 209 (2006) (describing “medication spellbinding” as a drug–induced
mental disability that prevents the victim, who is taking the drugs, from
realizing that the drug is not helping them function and feel better, but rather
is causing them to exhibit sometimes extreme behaviors, like violence towards
others and themselves, citing antidepressants as having a very common
occurrence of this “spellbinding”); see generally Ken Gillman, Serotonin Toxicity,
Serotonin
Syndrome,
PSYCHOTROPICAL
RESEARCH,
http://www.psychotropical.com/index.php/serotonin-toxicity (last updated Oct.
5, 2013) (describing serotonin toxicity as the side effects experienced after
ingesting an antidepressant and resulting in the “increase in the level of
serotonin synapses in the central nervous system[], which then excessively
stimulate all types of post synaptic serotonin receptors”).
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feelings of depression. 170 As stated at the beginning of this
Comment, if one out of every ten people over the age of twelve has
an antidepressant prescription, then the odds of having people
suffer from the inability to digest that drug, and not know that they
are unable to, can be relatively high. From a legal perspective, these
cases will undoubtedly become more numerous with the continual
rise of antidepressant prescriptions and knowledge that drugs, like
Effexor, have very severe and possible adverse reactions. 171
Ultimately, courts should recognize that antidepressant
prescription drugs can and do, in fact, play a part in homicide,
particularly where the Effexor drug label warns that thoughts of
homicide might occur. 172

C. How Can a Defendant Prove That the Drugs Induced
Murder?
Two members of the psychiatric field offer an answer. Dr.
David Healy is an internationally known and highly respected
psychiatrist, psychopharmacologist, scientist and author, who
testified in numerous cases in the United States and English
courts. 173 Similarly, Dr. Peter R. Breggin is a psychiatrist, medical
expert, researcher, and author. 174 Dr. Breggin testified in over
eighty civil and criminal cases, including the first case to address
the issue of antidepressants causing homicide in North America. 175
This case from Canada held that antidepressants played a culpable
role in the actions of a seventeen-year-old who murdered his
friend. 176 Both doctors have contributed many years of research and
170. See generally David Healy et al., Antidepressants and Violence:
Problems at the Interface of Medicine and Law, 3 PLOS MED. 1 (2006), available
at
http://www.davidhealy.org.php53-23.dfw1-1.websitetestlink.com/wpcontent/uploads/2012/05/2006-Healy-Herxheimer-Menkes-ViolenceAntidepressants1.pdf (finding that there are viable instances in which the law
will need to recognize that antidepressants played a part in the homicide, and
will need to reconcile where and how to allow this information into the courts).
171. NCHS, HEALTH, U.S. 2010, supra note 4, at 19; Pratt, supra note 6, at
1; Maggie Fox, Antidepressant Use Doubles in U.S., Study Finds, REUTERS
(Aug. 4, 2009), http://www.reuters.com/article/2009/08/04/us-antidepressantsusa-idUSTRE5725E720090804.
172. Healy et al., supra note 170, at 1, 4–5.
173. Dr. David Healy Bio, DR. DAVID HEALY, http://davidhealy.org/davidhealy-bio/ (last visited Mar. 21, 2015).
174. About Peter R. Breggin, M.D., BREGGIN.COM, http://breggin.com/index.
php?option=com_content&task=view&id=1&Itemid=41 (last visited Mar. 21,
2015).
175. Resume, Bibliography, and Legal Cases: Peter R. Breggin, M.D.,
BREGGIN.COM, http://breggin.com/resume.pdf (last visited Mar. 21, 2015)
[hereinafter Resume].
176. R. v. C.J.P., 2011 MBPC 62 (Can. Man. P.C. 2011) (finding that C.J.P.,
the defendant, did not deliberately plan the murder of his friend and that the
explanation offered by Dr. Breggin on the effect Prozac had on the defendant
was consistent with the evidence presented in the hearing, and holding that
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writing on the effects of antidepressants and the culpability of
defendants, as well in support of civil litigation against
pharmaceutical companies. 177 To support their automatism
defense, a criminal defendant should contact these doctors, 178 who
have been previously certified as expert witnesses, 179 or find other
psychiatrists or pharmacologists with special knowledge of
antidepressants and their effects.
The other component needed for a successful automatism
defense is the scientific evidence produced through blood and
genetic testing. 180 A criminal defendant can demonstrate that they
have biomarkers in their blood for higher levels of inflammation by
testing a blood sample. 181 They can also test their DNA profile for
genetic mutations on the specific alleles of the CYP450 gene that
are key in the creation of the enzymes needed to properly
breakdown and digest the antidepressant. 182 Although this testing
is currently not convenient, especially from an economic standpoint,
there are laboratories that will extract and process DNA to check
for any mutations. 183 Either of these tests can provide scientific
evidence in support of an automatism defense, and hopefully aid in
acquitting the defendant or serving as a mitigating factor in their
sentencing.
Another practicable way to prove the drugs had an adverse
effect on the defendant is through testimony from people who knew
the defendant before and after taking the drug. Elucidating on
different periods of time in the defendant’s life can prove quite
helpful. Testifying about the time before taking the prescribed
antidepressant, during the ingestion of the drug, and leading up to
the incident, can help to put the drug’s effect on the defendant into
perspective. Often times, those closest to the defendant are shocked
“the Prozac affected his behavior and judgment, thereby reducing his moral
culpability,” therefore the defendant was sentenced as a juvenile and not an
adult).
177. Books, DR. DAVID HEALY, http://davidhealy.org/books/ (last visited Mar.
21, 2015); Articles, DR. DAVID HEALY, http://davidhealy.org/articles/ (last visited
Mar. 21, 2015); Books, BREGGIN.COM, http://breggin.com/index.php?
option=com_content&task=blogcategory&id=15&Itemid=42 (last visited Mar.
21, 2015); Scientific Papers, BREGGIN.COM, http://breggin.com/index.php?op
tion=com_docman&Itemid=37 (last visited Mar. 21, 2015).
178. Contact Dr. Healy through his website at http://davidhealy.org/contactus/. Contact Dr. Breggin by consulting his phone and fax numbers, or email,
listed
on
his
website
at
http://breggin.com/index.
php?option=com_content&task=view&id=111.
179. Healy, supra note 173; Resume, supra note 175.
180. Kelland, supra note 156; Steenhuysen, supra note 157; Lucire, supra
note 158.
181. Kelland, supra note 156; Steenhuysen, supra note 157.
182. Lucire, supra note 158; Gillman, supra note 166.
183. Services such as these, and their pricing, are available from
laboratories like Independent Forensic Services. Information about IFS may be
found at http://www.ifscolorado.com.
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that she is facing murder charges. 184 This can be because of the
defendant’s disposition and reputation before taking the drug as
perceived by those people who know them well. Painting a picture
of the defendant as they are as a person not only humanizes her but
also makes her more relatable to a judge and jury who might then
seek mercy on this person who was also a victim. This person was
handed a prescription to help them feel better, but in reality they
were left with a toxic, ticking time bomb in their body. She was
unnecessarily a victim of Effexor and its adverse side effects.

D. When Courts Do Not Accept Automatism as a
Complete Defense, What Shall a Defendant Do?
Undoubtedly, there will be state judicial systems that do not,
and will not, accept the automatism defense. This does not mean
that a criminal defendant in those jurisdictions is left without hope.
Even where the automatism defense, and the evidence in support
thereof, will not exonerate the defendant, defense attorneys must
argue that the evidence be considered and substantially weighed in
the favor of the defendant when sentencing. Through a proper
presentation of the defense by providing the testimony of expert
witnesses with experience in the health, psychiatry, and
psychopharmacology fields, combined with testimony of the effect
the drug had on the defendant as observed and experienced by
others, the court should take into account the effect Effexor or any
antidepressant has on the user. This is not to say that all
defendants should present an automatism defense any time they
are faced with murder charges, but where defendants have a
legitimate explanation for why this murder occurred at their hands
as an adverse event and side effect to taking Effexor, this defense
and mitigating evidence should be considered and weighed. Only by
allowing this evidence to be heard can defendants who suffered
Effexor’s side effects, and who do not have a history of violence or
mental illness, have hope of a just outcome in their favor.

V.

CONCLUSION

When the courts are faced with trials for criminal defendants
who murdered someone while taking Effexor, they should allow the
automatism defense in support of the defendant’s inability to have
intended the death. The involuntary intoxication defense has been
on the “out” for a while now, and will not offer any success for a
criminal defendant in the United States. The better alternative is
the automatism defense. This defense allows the defendant to argue
that the drugs put them into such a state of unconsciousness that

184. SSRI Stories, supra note 24; RXISK, supra note 21.
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they could not reasonably have intended or acted of their own
volition at the time of the incident.
The pharmaceutical industry will continue to grow, especially
in light of the existing trend of writing Americans prescriptions for
antidepressants as part of a drug “cocktail.” With this growth comes
a great danger to the health of those seeking help from their
physicians, and potentially everyone who is in their lives. Courts
need to acknowledge that the side effects listed on the labels are
dire and very real. Additionally, courts should acknowledge that
taking antidepressants for some people leads to grave and unjust
consequences when their trusted physicians hand them ticking time
bombs. Therefore, courts need to change their understanding and
perception of criminal law as science continues to advance in order
to help “increase[] the courts’ understanding of human conduct and
relationships.” 185

185. Gorham v. United States, 339 A.2d 401, 432 (D.C. 1975) (Fickling, J.,
dissenting).
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